Re-Connect: A Randomised, Controlled, Open-Label, Multi-Centre Study to Evaluate the Efficacy of FeetMe® Home-Bases Rehabilitation Program in Comparison to Conventional Physiotherapy in Patients With Parkinson's Disease Using Connected Insoles

Sponsor
FeetMe (Industry)
Overall Status
Not yet recruiting
CT.gov ID
NCT05998265
Collaborator
University Hospital, Lille (Other)
150
2
24

Study Details

Study Description

Brief Summary

The goal of this clinical trial is to compare home based rehalitation program with real time biofeeback versus conventional physiotherapy on the gait velocity in Parkinson disease. The main question[s] it aims to answer are:

• How do the interventions afftect the gait velocity of the participants at week 12 ? Participants will be randomized to either follow prescribtional physiotherapy or FeetMe rehabilitation programs during the first 12 weeks.

At the end of 12 weeks, participants will choose in which arm they want to pursue for 12 aditionnal weeks.

Condition or Disease Intervention/Treatment Phase
  • Device: FeetMe rehabilitation
  • Other: Physiotherapy
N/A

Study Design

Study Type:
Interventional
Anticipated Enrollment :
150 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Masking:
None (Open Label)
Primary Purpose:
Supportive Care
Official Title:
A Randomised, Controlled, Open-Label, Multi-Centre Study to Evaluate the Efficacy of FeetMe® Home-Bases Rehabilitation Program in Comparison to Conventional Physiotherapy in Patients With Parkinson's Disease Using Connected Insoles
Anticipated Study Start Date :
Nov 1, 2023
Anticipated Primary Completion Date :
Nov 1, 2025
Anticipated Study Completion Date :
Nov 1, 2025

Arms and Interventions

Arm Intervention/Treatment
Experimental: FeetMe Rehabilitation arm

Device: FeetMe rehabilitation
Home based rehabilitation program with real time biofeedback using a connected device

Active Comparator: Conventional physiotherapy arm

Other: Physiotherapy
Conventional physiotherapy as prescribed by the neurologists

Outcome Measures

Primary Outcome Measures

  1. Gait velocity [Week 12]

    Change from baseline to Week 12 (Visit 3) in gait velocity (cm/s) assessed during the 6 Minutes Walk-Test (6MWT).

Secondary Outcome Measures

  1. Stance time variability [Week 12]

    Change from baseline to Week 12 (Visit 3) in Stance Time Variability assessed during the 6MWT.

Eligibility Criteria

Criteria

Ages Eligible for Study:
40 Years to 70 Years
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  • Written informed consent to participate in the study.

  • Male or female patients between 40 to 70 years of age, inclusive.

  • Body weight range of 40 kg to120 kg and a body mass index (BMI) of 18 to 34 kg/m2.

  • Diagnosis of Idiopathic Parkinson's disease (PD) according to UK Brain Bank Criteria (2/3 symptoms), with Hoehn and Yahr (H&Y) staging level 2, 2.5 or 3.

  • Disease onset of at least 3 years prior to enrolment.

  • Patients with a history of 50% of levodopa responsiveness based on motor signs.

  • On stable treatment of PD medication for at least 30 days before screening and with no expected major changes during the first 3 months of the study.

  • Prescription for physiotherapy available.

  • Ability to walk without aid for at least 6 minutes.

  • Shoe size between 35 - 46 (European Standard).

  • Intact skin on feet.

  • Adequate visual and auditory acuity to perform the rehabilitation program and the assessments in the Investigator's judgement.

  • Comfortable with the use of a smartphone. If assistance is required for the use of FeetMe technology, a caregiver or volunteer is fully available to assist the patient.

  • Willingness to be regularly contacted via phone-calls.

  • Willingness to suspend conventional physiotherapy treatment and start the FeetMe rehabilitation program, if applicable.

  • French speaker.

Exclusion Criteria:
  • Medical history indicating a Parkinsonian syndrome other than idiopathic PD.

  • Unable to walk without walking aid or presence of an injury preventing the patient to walk.

  • Any relevant comorbidity or vestibular/visual dysfunctions limiting locomotion or balance.

  • Clinically significant comorbidities which in the judgement of the investigator may preclude the reliable gait assessment of the patient.

  • Patients with poor wound healing or broken skin on the feet.

  • Patients with foot implants.

  • Montreal Cognitive Assessment (MoCA) score ≤ 24/30.

  • Patients with dementia.

  • Patients with apathy.

  • Participation in another clinical trial with an investigational drug/ therapeutic within the three months before screening and during the study, unless agreed by the Sponsor.

  • Patients who had Lee Silverman Voice Treatment (LSVT) Big therapy within the past 12 months or have it planned during the course of the study.

  • Patients with Deep Brain Stimulation planned during the first 12 weeks of the study.

  • Patients with pacemakers.

  • Patients performing vigorous exercise > three times a week, 30 mins or more per session.

Contacts and Locations

Locations

No locations specified.

Sponsors and Collaborators

  • FeetMe
  • University Hospital, Lille

Investigators

None specified.

Study Documents (Full-Text)

More Information

Publications

None provided.
Responsible Party:
FeetMe
ClinicalTrials.gov Identifier:
NCT05998265
Other Study ID Numbers:
  • 2023-A00150-45
First Posted:
Aug 18, 2023
Last Update Posted:
Aug 18, 2023
Last Verified:
Jul 1, 2023
Individual Participant Data (IPD) Sharing Statement:
No
Plan to Share IPD:
No
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
Yes
Product Manufactured in and Exported from the U.S.:
No
Keywords provided by FeetMe
Additional relevant MeSH terms:

Study Results

No Results Posted as of Aug 18, 2023